Design of Protease Stable Therapeutic Peptides by Non-Perturbative Modification
Award amount
$222,678Program and phase
STTR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VELUM INC
- Proposal award date
- 2018-08-07
- Contract end date
- 2019-07-31
- UEI
- Y5DJXLQZL6F8
- Solicitation number
- PA17-303
- Topic code
- 300
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Peptide YY triagonist weight loss drugs
- A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome
- Protease Stable N-Terminally Modified Therapeutic Peptides
- Triagonist Peptide Therapeutics for Neuroprotection
- A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
- Combinatorial pipeline for discovery of anti-GPCR Nanobodies
- Development of a GBP-based glycosylation analysis system
- Extended-release injectable gel for multi-day treatment of postoperative pain
- eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening
Research funding history
8 SBIR/STTR records share this UEI (2018–2025). Reported award amounts total $5,415,069. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services